According to a new report published by K D Market Insights, titled, “MiRNA Sequencing and Assay Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global miRNA sequencing and assay market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032.  The increasing adoption of miRNA sequencing and assay techniques in various research applications, including disease diagnostics, biomarker discovery, and drug development. Additionally, the rising awareness about the role of miRNAs in gene regulation and disease progression which is the major factors augmenting the growth of the global miRNA sequencing and assay market.

MiRNA sequencing offers higher accuracy, sensitivity, and specificity, allowing researchers to obtain comprehensive and detailed information about miRNA expression profiles. This has led to an increased adoption of miRNA sequencing techniques in various research applications. Which is further expected to create ample growth opportunities for the global miRNA sequencing and assay market during the forecast period i.e., 2023-2032. Moreover, substantial increase in research funding for genomics, particularly in the field of miRNA studies has propelled market expansion. Decreasing cost of sequencing, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global miRNA sequencing and assay market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the presence of leading research institutions and a well-established pharmaceutical industry.

According to product type, the sequencing consumables segment accounted for the largest market share in the miRNA sequencing and assay market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global miRNA sequencing and assay market is segmented into product type, technology, end user and region. Based on product type, the market is bifurcated into sequencing consumables, library preparation kits. Based on technology, it is classified into sequencing by synthesis, nanopore, ion semiconductor sequencing and SOLiD (sequencing by oligonucleotide ligation and detection). Based on end user, it is classified into clinical laboratory, life science organization, academia & research institute, contract research organizations.

The global miRNA sequencing and assay market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Light Therapy Market

·         On the basis of product type, the sequencing consumables segment accounted for the largest market share in the miRNA sequencing and assay market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

·         On the basis of region, North America accounted for the largest share in the global miRNA sequencing and assay market in 2022. The region is further projected to continue dominating in the market during the forecast period.

·         On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.

Some of the major miRNA sequencing and assay companies profiled in the report include Thermo Fisher Scientific, Inc; Illumina, Inc.; QIAGEN N.V.; PerkinElmer, Inc.; Abcam plc; New England Biolabs; Takara Bio Inc.; Lexogen GmbH; Norgen Biotek Corp.; Maravai LifeSciences; HTG Molecular Diagnostics, Inc.; Meridian Bioscience, Inc.; System Biosciences LLC.